



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**Role of Hepcidin as a biomarker for iron
status in patients on regular
hemodialysis after treatment
of hepatitis C virus**

A Thesis

Submitted For partial Fulfillment of Master degree
in Internal Medicine

By

Mohamed Adel Sharaf

M.B., B.Ch

Nephrology Resident at Nasser Institute for Treatment and Research

Under Supervision of

Prof. Dr. Magdy Mohamed El Sharkawy

*Professor of Internal Medicine and Nephrology
Faculty of Medicine, Ain Shams University*

Dr. Haitham Ezzat Abdelaziz

*Assistant Professor of Internal Medicine and Nephrology
Faculty of Medicine, Ain Shams University*

Dr. Lina Essam Khedr

*Lecturer of Internal Medicine and Nephrology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبب انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I am greatly honored to express my deep respect and gratitude to **Prof. Dr. Magdy Mohamed El Sharkawy**, Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for his faithful supervision, understanding, help and encouragement in initiating and completing this work.*

*I am very much obliged to **Dr. Haitham Ezzat Abdelaziz**, Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for his great help and support throughout all the steps of this work.*

*I am most grateful to **Dr. Lina Essam Khedr**, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for the efforts and time she has devoted to accomplish this work.*

Last but not least, I can't forget to thank all members of my family, specially my Parents and my fiancée, for pushing me forward in every step of my life.

*Mohamed Adel Sharaf
2020*



List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	v
Introduction	1
Aim of the Work.....	3
Review of literature	
End-stage renal disease	4
Anemia in end-stage renal disease	10
Hepcidin	17
Hepatitis C virus in patients on regular heamodialysis	29
Patients and methods	42
Results.....	46
Discussion	64
Summary	78
Conclusion and recommendations.....	83
References	84
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
ADPKD	: Autosomal dominant polycystic kidney disease
AI	: Anemia of inflammation
AKI	: Acute kidney injury
AVF	: Arteriovenous fistula
CHC	: Chronic hepatitis C
CKD	: Chronic kidney disease
COPD	: Chronic obstructive pulmonary disease
CPN	: Chronic pyelonephritis
CRRT	: Continuous renal replacement therapy
DAAs	: Direct acting antivirals
DM	: Diabetes Mellitus
eGFR	: Estimated glomerular filtration rate
ESA	: Erythropoiesis-Stimulating Agent
ESRD	: End stage renal disease
GIT	: Gastrointestinal tract
HAMP	: Hepcidin Antimicrobial Peptide
HB	: Heamoglobin
HCC	: Hepatocellular carcinoma
hCT	: Hematocrite value
HCV	: Hepatitis C virus
HD	: Heamodialysis
HH	: Hereditary Hemochromatosis
HJV	: Hemojuvelin
IDA	: Iron deficiency anemia
IFN	: Interferon

IHD	: Ischemic heart disease
IL-6	: Interleukin-6
IRES	: Internal ribosome entry site
KTx	: Kidney transplant
LEAP-1	: Liver- Expressed Antimicrobial Protein-1
LPS	: Lipopolysaccharide
MHD	: Maintenance hemodialysis
NSAID	: Non-steroidal anti-inflammatory drugs
OCI	: Occult hepatitis C virus infection
PD	: Peritoneal dialysis
PIH	: Pregnancy induced hypertension
PMNCs	: Polymorph nuclear cells
rhEPO	: Recombinant human erythropoietin
RRT	: Renal replacement therapy
SD	: Standard deviation
SLE	: Systemic lupus erthymatosis
SPSS	: Statistical package for social science
SVR	: Sustained virologic response
TfR2	: Transferrin Receptor 2
TIBC	: Total iron binding capacity
TIN	: Tubulointerstitial nephritis
TSAT	: Transferrin percentage saturation

List of Tables

Table No.	Title	Page No.
Table (1):	Distribution of the studied patients according to demographic characteristics	46
Table (2):	Distribution of the studied patients according to etiology of renal failure and associated comorbidity	47
Table (3):	Distribution of the studied patients according to viral markers	49
Table (4):	Distribution of the studied patients according to principals of hemodialysis	50
Table (5):	Distribution of the studied patients according to history of blood transfusion.....	52
Table (6):	Distribution of the studied patients according to history of epoetin and iron therapy	53
Table (7):	Distribution of the studied patients according to laboratory data	55
Table (8):	Relation between serum hepcidin and gender and dialysis access among the studied patients	56
Table (9):	Correlation between serum hepcidin and both age and principals of hemodialysis:	57
Table (10):	Relation between serum hepcidin and history of blood transfusion, epotein use and iron therapy among the studied patients	58
Table (11):	Correlation between serum hepcidin and	

	both age and laboratory data	59
Table (12):	Linear stepwise regression analysis of variables associated with serum hepcidin among the studied patients	63

List of Figures

Figure No.	Title	Page No.
Figure (1):	Support for more gradual deterioration into ESRF, will either take the form of HD or peritoneal dialysis (PD).	5
Figure (2):	Hemodialysis	8
Figure (3):	Causes of anemia in end-stage renal disease	12
Figure (4):	Regulation of body iron homeostasis by hepcidin.....	23
Figure (5):	Inflammatory mechanisms in chronic anemia	24
Figure (6):	The structure of the hepatitis C virus lipoviro-particle. E, envelope protein; RNA, ribonucleic acid.....	29
Figure (7):	Pie chart showing distribution of the studied patients according to gender	46
Figure (8):	Pie chart showing distribution of the studied patients according to cause of renal failure	48
Figure (9):	Pie chart showing distribution of the studied patients according to associated comorbidities	48
Figure (10):	Pie chart showing distribution of the studied patients according to dialysis access	51

Figure (11): Pie chart showing distribution of the studied patients according to frequency of epoetin use 54

Figure (12): Scatter dot graph showing significant negative correlation between serum hepcidin and hemoglobin..... 60

Figure (13): Scatter dot graph showing significant negative correlation between serum hepcidin and serum iron..... 60

Figure (14): Scatter dot graph showing significant positive correlation between serum hepcidin and TIBC..... 61

Figure (15): Scatter dot graph showing significant negative correlation between serum hepcidin and serum ferritin..... 61

Figure (16): Scatter dot graph showing significant positive correlation between serum hepcidin and transferrin saturation 62

Abstract

Background: Heparin, an acute phase reactant protein produced in the liver, is a key regulator of iron homeostasis. Because of its renal elimination and regulation by inflammation, it is possible that progressive renal insufficiency leads to altered heparin metabolism. **Aim of the Work:** to assess effect of HCV treatment on heparin levels in regular hemodialysis patients and its relation to iron status. **Patients and Methods:** This cross sectional study was conducted on 45 ESRD patients on regular hemodialysis. All candidates included in this study subjected to careful history taking, full clinical examination and investigations (including complete blood count, HCVAb, HBVAg and HIVAb). **Results:** In our study, dry weight ranged from 46 to 117 kg with mean 77.36. Weight gain ranged from 2 to 5 kg with mean 3.09. About 87% of patients had LTAVF access. About 12 patients (27%) received blood transfusion once. Timing of transfusion ranged from 4 to 60 month with median of 24 months. Regarding frequency of epoetin dose, 11 patients (24.4%) did not receive epoetin, 16 patients (35.6%) received it twice/week. Only 3 patients (6.7%) received iron therapy for time ranging from 3 to 5 months with mean of 4 months. Mean Hb concentration in our study population was 10.11 ± 1.64 gm/dl. The mean of iron was 64.22 ± 19.52 , TIBC was 409.96 ± 67.85 , ferritin was 394.56 ± 239.22 and TSAT% was 22.6 ± 7.36 . The mean serum heparin was 218.51 ± 127 . Our study demonstrated that increase in serum heparin is associated with lower serum Hb and iron levels. On the other hand, there is statistically significant positive correlation between serum heparin and both serum ferritin and transferrin saturation. **Conclusion:** Median heparin value is elevated in dialysis ESRD patients due to increased inflammation and decreased clearance of heparin. Also serum heparin levels were lowered in HCV patients. Therefore ESRD patients on maintenance HD after treatment of HCV infection showed elevated levels of serum heparin.

Key words: Heparin, iron status, regular hemodialysis, hepatitis C virus

Introduction

Anemia is an important and common problem associated with chronic kidney disease (CKD), which is caused by erythropoietin deficiency, iron-restricted erythropoiesis (*Ueda & Takasawa, 2017*).

Adequate iron stores are essential for achieving maximum benefit from erythropoietic agents, such as recombinant human erythropoietin (rhEPO). Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents (*Weiler et al., 2015*).

Ferritin is a marker of tissue iron stores, whereas TSAT is a marker of iron available for erythropoiesis in the circulation. TSAT is calculated as follows: (serum ferritin/total iron binding capacity) × 100. Absolute or true IDA is present when the body iron stores are low and usually is represented by ferritin levels less than 100 ng/mL in predialysis and peritoneal dialysis patients and by ferritin levels less than 200 ng/mL in hemodialysis patients and a TSAT less than 20% (*Rocha et al., 2009*).

Hepcidin, an acute phase reactant protein produced in the liver, is a key regulator of iron homeostasis. Hepcidin inhibits intestinal iron absorption and iron release from macrophages and hepatocytes. Because hepcidin productions